Volume 85 Issue 39 | p. 45 | Concentrates
Issue Date: September 24, 2007

GSK Wins U.S. Antibiotic Contract

Department: Business
News Channels: Nano SCENE

GlaxoSmithKline has scored a Department of Defense contract worth up to $41 million over five years to develop a new class of antibiotics. Under the contract, GSK will identify antibacterials targeting gram-negative biothreats as well as conventional gram-negative hospital pathogens, which have become increasingly resistant to current treatments. Gram-negative bacteria, which include Pseudomonas, Klebsiella, and Acinetobacter, are particularly tricky to combat due to an outer membrane that can keep drugs from reaching the bacterial cell. GSK will work on developing drugs that can first penetrate that barrier and then kill the pathogen.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment